Articles

In an analysis of more than 10,000 relapsed/refractory patients treated in routine clinical practice with ixazomib/lenalidomide/dexamethasone, outcomes were as good as those reported in clinical trials. Read More ›

What is Minimal Residual Disease (MRD) Negativity?

Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients. Read More ›

Multiple Myeloma as a Chronic Disease

In Relapsed or Refractory Myeloma, Addition of Elotuzumab to Lenalidomide + Dexamethasone Improves Outcomes with No Detriment to Quality of Life

As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients. Read More ›

Adding Elotuzumab to Pomalidomide, Bortezomib, and Dexamethasone Leads to Promising Responses in Relapsed/Refractory Multiple Myeloma

Final analysis of patient-reported outcomes from the phase 3 ELOQUENT-2 trial confirms elotuzumab has no negative impact on health-related quality of life. Read More ›

In patients with relapsed/refractory multiple myeloma, treatment with elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone shows encouraging responses, with manageable toxicity. Read More ›

Triplets versus Quads

Leslie Lauersdorf explains triplet versus quad regimens in relation to multiple myeloma. Read More ›

CAR T-Cell Data in Multiple Myeloma

COLUMBA Update: Subcutaneous Daratumumab Shows Similar Efficacy to IV Formulation in Relapsed/Refractory Multiple Myeloma, with Fewer Adverse Events

Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma. Read More ›

Novel Myeloma Regimen Improves Outcomes in Systemic AL Amyloidosis

Compared with intravenous (IV) administration, subcutaneous daratumumab led to similar response rates with fewer infusion-related reactions. Read More ›

In systemic amyloid light chain (AL) amyloidosis, treatment with ixazomib/dexamethasone proved more beneficial than treatment of physician’s choice, although hematologic response was not improved. Read More ›

Latest Developments in Multiple Myeloma